Advancements in technology and a growing emphasis on ethical considerations are shaping the future of in vivo testing. Innovations such as organ-on-a-chip and in silico modeling offer promising alternatives that may eventually reduce the need for animal testing. Moreover, a shift towards personalized medicine is driving the development of patient-derived xenograft models, which allow for more individualized and accurate assessments.
In conclusion, in vivo tests remain a vital component of toxicology, providing essential data for evaluating the safety of substances. While challenges and ethical concerns persist, ongoing advancements and a commitment to humane research practices continue to enhance the field.
